{
  "paper_id": "PMC10962051",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962051/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Reference level of evidence by payer.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/24fdb28569d5/10.1177_24730114241239310-fig1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/24fdb28569d5/10.1177_24730114241239310-fig1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/24fdb28569d5/10.1177_24730114241239310-fig1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/24fdb28569d5/10.1177_24730114241239310-fig1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig1-24730114241239310",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/24fdb28569d5/10.1177_24730114241239310-fig1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10962051/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/24fdb28569d5/10.1177_24730114241239310-fig1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Number and percentage of references cited by each payer that mention their specific coverage criteria.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig2-24730114241239310",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10962051/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg"
    }
  },
  "claims": [
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem\nAnthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna\nCigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation\nHealth Care Services Corporation had 33 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark\nHighmark had 15 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare\nUnited Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Discussion\nThe results of this study demonstrate that in their coverage policies for TAA, commercial insurance payers cite poor quality references, occasionally cite their references improperly in the policy document, and are forced to rely on low–level of evidence studies to formulate their specific coverage criteria.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem\nAnthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna\nCigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation\nHealth Care Services Corporation had 33 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark\nHighmark had 15 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare\nUnited Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Discussion\nThe results of this study demonstrate that in their coverage policies for TAA, commercial insurance payers cite poor quality references, occasionally cite their references improperly in the policy document, and are forced to rely on low–level of evidence studies to formulate their specific coverage criteria.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem\nAnthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna\nCigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation\nHealth Care Services Corporation had 33 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark\nHighmark had 15 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare\nUnited Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Discussion\nThe results of this study demonstrate that in their coverage policies for TAA, commercial insurance payers cite poor quality references, occasionally cite their references improperly in the policy document, and are forced to rely on low–level of evidence studies to formulate their specific coverage criteria.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem\nAnthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna\nCigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation\nHealth Care Services Corporation had 33 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark\nHighmark had 15 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare\nUnited Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Discussion\nThe results of this study demonstrate that in their coverage policies for TAA, commercial insurance payers cite poor quality references, occasionally cite their references improperly in the policy document, and are forced to rely on low–level of evidence studies to formulate their specific coverage criteria.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem\nAnthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna\nCigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation\nHealth Care Services Corporation had 33 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark\nHighmark had 15 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare\nUnited Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Discussion\nThe results of this study demonstrate that in their coverage policies for TAA, commercial insurance payers cite poor quality references, occasionally cite their references improperly in the policy document, and are forced to rely on low–level of evidence studies to formulate their specific coverage criteria.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem\nAnthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna\nCigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation\nHealth Care Services Corporation had 33 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark\nHighmark had 15 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare\nUnited Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Discussion\nThe results of this study demonstrate that in their coverage policies for TAA, commercial insurance payers cite poor quality references, occasionally cite their references improperly in the policy document, and are forced to rely on low–level of evidence studies to formulate their specific coverage criteria.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem\nAnthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna\nCigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation\nHealth Care Services Corporation had 33 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark\nHighmark had 15 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare\nUnited Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Discussion\nThe results of this study demonstrate that in their coverage policies for TAA, commercial insurance payers cite poor quality references, occasionally cite their references improperly in the policy document, and are forced to rely on low–level of evidence studies to formulate their specific coverage criteria.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem\nAnthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna\nCigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation\nHealth Care Services Corporation had 33 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark\nHighmark had 15 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare\nUnited Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Discussion\nThe results of this study demonstrate that in their coverage policies for TAA, commercial insurance payers cite poor quality references, occasionally cite their references improperly in the policy document, and are forced to rely on low–level of evidence studies to formulate their specific coverage criteria.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem\nAnthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna\nCigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation\nHealth Care Services Corporation had 33 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark\nHighmark had 15 references that were analyzed.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare\nUnited Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Commercial Payer\nLOE I\nLOE II\nLOE III\nLOE IV\nLOE V\nUnable to be Determined\n\n\n\nAetna\n1\n9\n36\n55\n8\n6\n\n\nAnthem\n1\n10\n19\n19\n0\n1\n\n\nCigna\n2\n6\n22\n20\n6\n3\n\n\nHCSC\n0\n2\n3\n24\n4\n0\n\n\nHighmark\n1\n1\n2\n10\n0\n1\n\n\nUnited Healthcare\n1\n0\n1\n0\n0\n4\n\n\nTotals, n (%)\n4 (1.7)\n24 (10.1)\n71 (29.8)\n108 (45.4)\n17 (7.1)\n14 (5.9)\n\n\n\nOpen in a new tab\nAbbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FDA Approved Implant, n (%)\nMentions Skeletal Maturity, n (%)\nFailure of Conservative Management, n (%)\nSevere Pain, n (%)\nLoss of Function or Mobility, n (%)\nAdvanced Ankle Arthritis, n (%)\nArthritis of Adjacent Joints, n (%)\nSevere Arthritis of Contralateral Ankle, n (%)\nArthrodesis (Fusion) of Contralateral Ankle, n (%)\nPresence of Inflammatory Arthritis (eg, Rheumatoid), n (%)\nAdequate Lower-Extremity Vascular Perfusion, n (%)\n\n\n\nAetna\n61 (53.0)\n10 (8.7)\n2 (1.7)\n44 (38.3)\n35 (30.4)\n104 (90.4)\n10 (8.7)\n16 (13.9)\n11 (9.6)\n81 (70.4)\n35 (30.4)\n\n\nAnthem\n31 (62.0)\n5 (10.0)\n1 (2.0)\n7 (14.0)\n11 (22.0)\n37 (74.0)\n5 (10.0)\n0 (0.0)\n8 (16.0)\n18 (36.0)\n19 (38.0)\n\n\nCigna\n38 (64.4)\n7 (11.9)\n2 (3.4)\n16 (27.1)\n20 (33.9)\n46 (78.0)\n3 (5.1)\n4 (6.8)\n2 (3.4)\n25 (42.4)\n26 (44.1)\n\n\nHCSC\n23 (69.7)\n0 (0.0)\n2 (6.1)\n13 (39.4)\n10 (30.3)\n25 (75.8)\n3 (9.1)\n3 (9.1)\n5 (15.2)\n26 (78.8)\n12 (36.4)\n\n\nHighmark\n4 (26.7)\n1 (6.7)\n1 (6.7)\n6 (40.0)\n4 (26.7)\n14 (93.3)\n1 (6.7)\n0 (0.0)\n0 (0.0)\n12 (80.0)\n3 (20.0)\n\n\nUnited\n0 (0.0)\n2 (33.3)\n1 (16.7)\n6 (100.0)\n5 (83.3)\n6 (100.0)\n2 (33.3)\n0 (0.0)\n0 (0.0)\n1 (16.7)\n1 (16.7)\n\n\nTotal\n135 (56.7)\n22 (9.2)\n6 (2.5)\n80 (33.6)\n74 (31.1)\n199 (83.6)\n22 (9.2)\n18 (7.6)\n23 (9.7)\n139 (58.4)\n86 (36.1)\n\n\n\nOpen in a new tab\nAbbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 174,
    "images_downloaded": 2,
    "tables_filtered": 0
  }
}